MediumCardiologyHeart failure with reduced ejection fractionca-mccqe1ca-rcpsc-im
A 67-year-old man with heart failure with reduced ejection fraction (EF 30%) remains symptomatic (NYHA II-III) despite optimal doses of an ACE inhibitor and evidence-based beta blocker. According to the CCS heart failure guideline, which additional medication class should be part of his core foundational regimen if no contraindications exist?